Autonomic Pharmacology: Cholinergic Agonists - Ninja Nerd Lecture Notes

1. Summary

This Ninja Nerd lecture provides a comprehensive overview of Cholinergic Agonists within the context of autonomic pharmacology. Professor Zach Murphy begins by reviewing the autonomic nervous system and the pivotal role of acetylcholine (ACh). The lecture then categorizes cholinergic agonists into direct-acting (binding directly to muscarinic or nicotinic receptors) and indirect-acting (inhibiting acetylcholinesterase) agents. It delves into their mechanisms of action, receptor specificity (muscarinic vs. nicotinic), therapeutic uses with specific drug examples (e.g., bethanechol, pilocarpine, physostigmine), and potential adverse effects. The lecture utilizes visual aids to enhance understanding and concludes with practice problems.

2. Key Takeaways

* **Cholinergic agonists** mimic or enhance the effects of acetylcholine (ACh) in the body.

* ACh is a primary neurotransmitter in both the sympathetic and parasympathetic nervous systems, as well as the somatic nervous system.

* Cholinergic agonists are classified as **direct-acting** (bind to receptors) or **indirect-acting** (inhibit ACh breakdown).

* **Direct-acting agonists** can target **muscarinic receptors** (G protein-coupled receptors) or **nicotinic receptors** (ligand-gated ion channels).

* **Indirect-acting agonists** work by inhibiting acetylcholinesterase (AChE), leading to increased ACh levels at the synapse.

* Understanding the specific receptor subtype (M1-M5, Nn, Nm) and its location is crucial for predicting drug effects.

* Clinical applications of cholinergic agonists range from treating urinary retention and glaucoma to managing Alzheimer's disease and myasthenia gravis.

* Adverse effects are often extensions of the drug's intended pharmacological action and can be significant.

3. Detailed Notes

---

**I. Introduction to Cholinergic Agonists (0:07)**

* **Definition:** Drugs that activate cholinergic receptors, mimicking the effects of acetylcholine (ACh).

* **Importance:** Crucial for understanding the parasympathetic nervous system and its modulation.

---

**II. The Cholinergic System (0:43)**

* **Autonomic Nervous System (ANS) Overview:**

* Controls involuntary bodily functions.

* Composed of the Sympathetic and Parasympathetic nervous systems.

* **Parasympathetic Nervous System (PNS):** "Rest and Digest." Generally responsible for conservation and restoration of energy.

* **Neurotransmitter:** Acetylcholine (ACh) at both preganglionic and postganglionic synapses.

* **Sympathetic Nervous System (SNS):** "Fight or Flight." Generally mobilizes the body during activity.

* **Neurotransmitter:** ACh at preganglionic synapses, Norepinephrine (NE) at most postganglionic synapses (except sweat glands, which use ACh).

* **Acetylcholine (ACh):**

* **Synthesis:** Synthesized in the presynaptic terminal from choline and acetyl-CoA by the enzyme choline acetyltransferase (ChAT).

* **Storage:** Stored in vesicles.

* **Release:** Released into the synaptic cleft upon nerve impulse.

* **Action:** Binds to cholinergic receptors on the postsynaptic membrane, causing a response.

* **Degradation:** Rapidly hydrolyzed by acetylcholinesterase (AChE) in the synaptic cleft into choline and acetic acid. Choline is reuptaken by the presynaptic terminal.

---

**III. Cholinergic Receptors and Agonists (11:11)**

* **Types of Cholinergic Receptors:**

* **Muscarinic Receptors:**

* **Type:** G protein-coupled receptors (GPCRs).

* **Location:** Found on effector cells innervated by postganglionic parasympathetic neurons, sweat glands (innervated by sympathetic cholinergic neurons), blood vessels (endothelium), and the central nervous system (CNS).

* **Subtypes (M1-M5):**

* **M1:** CNS, autonomic ganglia, gastric parietal cells. Action: Increased secretions, CNS excitation.

* **M2:** Heart (SA node, AV node, atria, ventricles). Action: Decreased heart rate, decreased contractility (atria), decreased conduction velocity.

* **M3:** Smooth muscle (bronchi, GI tract, bladder detrusor, iris sphincter, ciliary muscle), vascular endothelium. Action: Contraction of smooth muscle, vasodilation (indirectly via NO release from endothelium), increased secretions, pupil constriction (miosis), accommodation.

* **M4:** CNS (brain). Action: Inhibitory, autoreceptor.

* **M5:** CNS (brain). Action: Vasodilation in cerebral vasculature, dopamine release.

* **Nicotinic Receptors:**

* **Type:** Ligand-gated ion channels (ionotropic receptors).

* **Location:** Found at neuromuscular junctions (NM) and autonomic ganglia (Nn), as well as the CNS.

* **Subtypes:**

* **Nn (Neuronal):** Autonomic ganglia (both sympathetic and parasympathetic), adrenal medulla, CNS. Action: Depolarization of the postsynaptic neuron/adrenal medulla, leading to excitation.

* **Nm (Muscular):** Neuromuscular junction (skeletal muscle). Action: Depolarization of the muscle fiber membrane, leading to muscle contraction.

* **Classification of Cholinergic Agonists:**

* **Direct-Acting Agonists:**

* Bind directly to and activate muscarinic or nicotinic receptors.

* **Examples:**

* **Choline Esters:**

* **Acetylcholine (ACh):** Rarely used clinically due to rapid hydrolysis by AChE and non-specific effects.

* **Methacholine:** Primarily muscarinic agonist, used in bronchial challenge tests for asthma diagnosis.

* **Bethanechol:** Primarily muscarinic agonist (M3 selective), resistant to AChE. Used to treat urinary retention and gastric atony.

* **Carbachol:** Muscarinic and nicotinic agonist. Used topically in the eye for glaucoma (miosis, aqueous humor outflow).

* **Natural Alkaloids:**

* **Pilocarpine:** Muscarinic agonist, resistant to AChE. Used topically for glaucoma (miosis, increased outflow) and orally for xerostomia (dry mouth, e.g., after radiation therapy).

* **Muscarine:** Found in poisonous mushrooms, primarily acts on muscarinic receptors.

* **Nicotine:** Acts on nicotinic receptors in ganglia and CNS.

* **Indirect-Acting Agonists (Cholinesterase Inhibitors):**

* Do not bind directly to the receptor but inhibit the enzyme acetylcholinesterase (AChE).

* This prevents the breakdown of ACh, increasing its concentration in the synaptic cleft and prolonging its action.

* **Types:**

* **Reversible Inhibitors:** Bind to AChE for a moderate duration.

* **Examples:**

* **Edrophonium:** Short-acting, used diagnostically for myasthenia gravis (Tensilon test).

* **Physostigmine:** Tertiary amine, can cross the blood-brain barrier (BBB). Used to treat anticholinergic overdose (e.g., atropine poisoning).

* **Neostigmine:** Quaternary amine, does not cross BBB. Used to treat myasthenia gravis and reverse neuromuscular blockade.

* **Pyridostigmine:** Quaternary amine, does not cross BBB. Used for chronic treatment of myasthenia gravis.

* **Donepezil, Rivastigmine, Galantamine:** Used to treat Alzheimer's disease by increasing ACh levels in the CNS.

* **Irreversible Inhibitors:** Form a very strong, often covalent, bond with AChE, leading to prolonged inhibition.

* **Examples:** Organophosphates (e.g., Malathion, Parathion, Sarin gas). Highly toxic, can cause severe cholinergic crisis.

---

**IV. Clinical Indications and Adverse Effects of Agonists (32:56)**

* **Therapeutic Uses:**

* **Urinary Retention:** Bethanechol (stimulates detrusor muscle contraction).

* **Glaucoma:** Pilocarpine, Carbachol (miosis reduces intraocular pressure by increasing aqueous humor outflow).

* **Xerostomia (Dry Mouth):** Pilocarpine (stimulates salivary glands).

* **Myasthenia Gravis:** Physostigmine, Neostigmine, Pyridostigmine (increase ACh at NMJ to improve muscle strength).

* **Alzheimer's Disease:** Donepezil, Rivastigmine, Galantamine (increase ACh in CNS to improve cognitive function).

* **Reverse Neuromuscular Blockade:** Neostigmine (after surgery).

* **Anticholinergic Poisoning:** Physostigmine (crosses BBB to counteract central anticholinergic effects).

* **Diagnostic Tests:** Methacholine (asthma), Edrophonium (myasthenia gravis).

* **Adverse Effects (often extensions of intended effects - "SLUDGE/BBB" for muscarinic effects):**

* **Cardiovascular:** Bradycardia, hypotension, AV block (M2 effects).

* **Gastrointestinal:** Nausea, vomiting, diarrhea, abdominal cramps, increased salivation, increased gastric motility (M3 effects).

* **Respiratory:** Bronchoconstriction, increased bronchial secretions (M3 effects, problematic in asthma/COPD).

* **Ocular:** Miosis (pupil constriction), blurred vision, accommodative spasm (M3 effects).

* **Urinary:** Urinary urgency, incontinence (M3 effects).

* **Sweat Glands:** Increased sweating (M3/cholinergic sympathetic effects).

* **CNS (for agents crossing BBB):** Dizziness, confusion, seizures, respiratory depression, coma (especially with irreversible inhibitors or high doses).

* **Nicotinic Effects (at high doses or with specific agents):** Muscle fasciculations, tremors, paralysis (NM blockade).

* **Contraindications:**

* Asthma, COPD, or other obstructive airway diseases (due to bronchoconstriction).

* Peptic ulcer disease (increased gastric acid).

* Bradycardia, heart block.

* Hyperthyroidism (risk of atrial fibrillation).

* Mechanical obstruction of the bladder or GI tract.

* Hypersensitivity to the drug.

---

**V. Cholinergic Agonists Practice Problems (1:03:09)**

* *This section would typically involve case studies and questions designed to test application of the knowledge learned, such as identifying the appropriate drug for a given condition, predicting effects, or recognizing contraindications.*

---

**VI. Conclusion and Resources**

* **Professor's Website:** https://www.ninjanerd.org

* **Notes and Illustrations:** Available on the website.

* **Pharmacology Source:** Lippincott Illustrated Reviews: Pharmacology.

* **Social Media & Community Links:** Provided in the video description.

---